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AbstrAct
Background Constitutive activation of HER2-dependent 
intracellular signalling by HER2 gene amplification or by 
HER2 mutations has been demonstrated as a mechanism of 
primary and secondary cancer resistance to cetuximab or 
panitumumab in preclinical and clinical models of metastatic 
colorectal cancer (mCRC). Both HER2 Amplification for 
Colorectal Cancer Enhanced Stratification (HERACLES) cohort 
A and My Pathway clinical trials provided clinical evidence 
that anti-HER2 therapies could be active in these patients.
Patient and methods HER2 gene amplification and 
HER2 protein overexpression analysis were performed 
in tumour tissue by fluorescence in situ hybridisation 
and immunohistochemistry. HER2 positivity was defined 
according to HERACLES CRC-specific HER2 scoring criteria. 
DNA analysis for multiple assessment of gene mutations 
or amplifications was carried out with the next-generation 
sequencing (NGS) Ion AmpliSeq Colon and Lung Cancer 
Panel and by using a more extensive targeted high-multiplex 
PCR-based NGS panel (OncoMine Comprehensive Assay).
Results We report the clinical case of a patient with 
HER2 gene amplified and RAS/BRAF wild-type mCRC who 
experienced a long lasting and relevant clinical efficacy 
from sequential anti-HER2 therapies (trastuzumab plus 
lapatinib, pertuzumab plus trastuzumab, trastuzumab 
emtansine, trastuzumab plus capecitabine) achieving a 
cumulative clinical benefit of 29 months, after failure of 
the first three lines of standard treatments, which included 
all the potentially active drugs in mCRC, and which 
accounted for only 14 months of disease control. HER 
gene amplification was confirmed by NGS on two different 
metastatic lesions during the evolution of the disease.
Conclusion The clinical case highlights the role of HER2 gene 
amplification as a key genetic driver of cancer development 
and progression in mCRC and suggests that sequential HER2 
blockade could be a potential therapeutic strategy.
IntRoduCtIon
Epidermal growth factor receptor (EGFR) 
is one of the most characterised molec-
ular targets in metastatic colorectal 
cancer (mCRC). Two anti-EGFR blocking 
monoclonal antibodies (moAbs), cetuximab 
and panitumumab, are currently approved 
for treatment. However, the presence of 
gene alterations in the EGFR-activated down-
stream intracellular signalling pathways or in 
other tyrosine kinase receptors could impair 
the clinical efficacy of anti-EGFR moAbs, 
leading to primary or intrinsic cancer cell 
resistance.1–3 In this respect, RAS gene muta-
tions (KRAS and NRAS exons 2, 3 and 4) are 
the only biomarkers currently used in clinical 
Key questions
What is already known about this subject?
HER2 gene amplification or HER2 activating mutations 
have been implicated as one of the mechanisms for 
cancer cell resistance to anti-epidermal growth factor 
receptor (EGFR) therapies in metastatic colorectal 
cancer (mCRC). First reports from clinical trials 
provided clinical evidence that anti-HER2 therapies 
could be active in these patients.
What does this study add?
Here we report a clinical case of a patient with HER2-
amplified mCRC tumour highlighting its role as a key 
genetic driver of cancer development and progression. 
We demonstrated how sequential HER2-directed 
therapies were a highly effective therapeutic strategy 
after failure of standard treatments for mCRC.
How might this impact on clinical practice?
Our data, in agreement with large body of preclinical 
and clinical evidence, support the need to identify 
HER2 gene amplification in mCRC because it defines a 
relatively homogeneous subset of patients with mCRC 
with intrinsic resistance to EGFR-targeted therapy that 
could have a significant clinical benefit from anti-HER2 
treatments.
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practice as predictive of intrinsic resistance to anti-EGFR 
therapies.4 5
HER2 gene amplification or HER2 activating mutations 
have been implicated as one of the mechanisms for cancer 
cell resistance to anti-EGFR therapies in mCRC. The first 
evidence of HER2 as a potential target in mCRC derived 
from studies in mCRC xenograft models of RAS wild-type 
(WT) tumours, which were resistant to cetuximab treat-
ment. In this respect, Bertotti and colleagues identified 
HER2 amplification as a potential mechanism of primary 
resistance to cetuximab, in KRAS, NRAS, BRAF and 
PIK3CA WT tumours.6 In a large platform of patient-de-
rived tumour xenografts (PDTX), HER2 gene amplifica-
tion was found only in a small percentage (2%–3%) of 
genetically unselected patients with mCRC. However, 
in patients with KRAS WT mCRC, whose tumours were 
resistant to cetuximab treatment, the frequency of HER2 
gene amplification raised to 13.6%, whereas it increased 
to 36% in cetuximab-resistant KRAS, NRAS, BRAF and 
PIK3CA WT tumours. HER2 gene amplification was 
demonstrated as a relevant molecular driver for these 
tumours, suggesting that anti-HER2 therapy could be 
effective in a selected subset of patients with mCRC. The 
combined treatments with trastuzumab (an anti-HER2 
moAb) and lapatinib (a small molecule tyrosine kinase 
inhibitor against HER2 and, potentially, against EGFR) or 
with trastuzumab and pertuzumab (an anti-HER2 moAb 
that could block HER2/HER3 heterodimerisation) 
induced significant tumour regressions in HER2-ampli-
fied mCRC PDTX models.6
The role of HER2 in cancer resistance to anti-EGFR 
moAbs in mCRC has been also investigated by Yonesaka 
and colleagues, which reported increased HER2 signal-
ling, either by HER2 gene amplification or through 
enhanced production of the HER3-activating ligand 
heregulin, as a mediator of colon cancer cell resistance 
to cetuximab. Activation of HER2 induced extracellular 
signal-regulated kinase 1/2 signalling and, as a conse-
quence, cetuximab resistance in a panel of human colon 
cancer cell lines.7 Inhibition of HER2 signalling or 
disruption of HER2/HER3 heterodimerisation restored 
cetuximab sensitivity both in vitro and in vivo in these 
colon cancer models. These findings were extended 
to a cohort of patients with mCRC with either intrinsic 
or acquired resistance to cetuximab therapy. In fact, in 
these cases, HER2 gene amplification in tumour samples 
or high levels of circulating heregulin in patient plasma 
were found.7
The Cancer Genome Atlas project identified HER2 
gene amplification as well as HER2 gene mutations in 
CRC.8 Activating HER2 gene mutations could be equally 
important for determining resistance to anti-EGFR 
therapy in CRC. In fact, Kavuri et al have demonstrated 
that the introduction of activating HER2 gene mutations 
(S310F, L755S, V777L, V841I and L866M) in colon cells 
increased HER2-activated signalling pathways, anchor-
age-independent cell growth, and determined cell resis-
tance to cetuximab or to panitumumab treatment with 
sustained mitogen-activated protein kinase phosphoryla-
tion. Treatments of mice-bearing HER2-mutated PDTX 
with trastuzumab, neratinib (a small molecule anti-HER2 
tyrosine kinase inhibitor) or lapatinib, as single agents or 
in combination, determined tumour regression.9
A few studies have explored the feasibly and the poten-
tial activity of the anti-HER2 moAb trastuzumab in combi-
nation with irinotecan or oxaliplatin-based chemotherapy 
in patients with mCRC. However, these studies were 
performed in unselected patients and did not provide 
useful information on the clinical efficacy of this thera-
peutic approach.10 11 Therefore, for more effective studies 
exploring the potential role of anti-HER2 therapies in 
patients with mCRC, a methodology for HER2 testing 
that could be used for the appropriate patient selec-
tion was needed. A study to define the criteria for HER2 
gene amplification and protein expression in mCRC was 
recently conducted by a panel of pathologists within the 
HER2 Amplification for Colorectal Cancer Enhanced 
Stratification (HERACLES) programme.12 This was done 
in two steps. First, pathologists adapted fluorescence in 
situ hybridisation (FISH) and immunohistochemistry 
(IHC) protocols, which are currently used for defining 
HER2 positivity in human breast and gastric cancer, to 
CRC. In the second step, these criteria were prospectively 
validated to screen and identify patients with HER2-posi-
tive mCRC. Five per cent of patients with KRAS WT mCRC 
were found to have HER2-positive tumours, according to 
CRC-specific HER2 scoring criteria.12
Several clinical trials are currently ongoing following 
selection of patients with HER2-positive mCRC (table 1). 
In this respect, HERACLES is a series of proof-of-con-
cept phase II clinical trials that have been designed to 
test different anti-HER2 treatments. The HERACLES 
cohort A study has been conducted in patients with KRAS 
exon 2 WT, HER2-amplified mCRC, whose tumours were 
resistant to standard therapies, including anti- EGFR 
moAbs.13 Patients were treated with the combination of 
trastuzumab and lapatinib. Forty-eight out of 914 KRAS 
exon 2 WT tumours (5%), which were screened, were 
positive according to CRC-specific HERACLES HER2 
scoring criteria. Eight of the 27 patients enrolled in the 
trial (30%) achieved an objective response, of which one 
patient (4%) had a complete response and seven patients 
(26%) had partial responses (PR). In addition, 12 
patients (44%) had stable disease (SD) as best response. 
The median duration of the response was 38 weeks with 
median progression-free survival (PFS) of 21 weeks and 
median overall survival of 46 weeks. Notably, responses 
were significantly more common and PFS was longer in 
patients whose tumours had high levels of HER2 gene 
amplification. The combined anti-HER2 treatment with 
trastuzumab and lapatinib had an acceptable safety profile, 
with most toxic effects being of grade 1 or 2. No cardio-
toxicity was reported. The HERACLES-RESCUE clinical 
trial is currently treating patients following progression to 
trastuzumab plus lapatinib therapy from the HERACLES 
cohort A trial with trastuzumab emtansine (T-DM1). 
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Finally, the HERACLES cohort B clinical trial is currently 
recruiting patients with HER2 therapy-naïve, HER2-pos-
itive mCRC for the treatment with T-DM1 plus pertu-
zumab. Moreover, the role of anti-HER2 therapy with 
trastuzumab plus pertuzumab in patients with mCRC with 
either HER2-amplified or HER2-mutated tumours, which 
could be identified by next-generation sequencing (NGS) 
and/or by IHC or FISH, is currently evaluated in the My 
Pathway phase II clinical trial.14 Preliminary results on 
34 patients have been reported. Twelve patients had PR 
as best response, with SD longer than 4 months in three 
additional patients for an overall response rate of 37.5%. 
These responses were durable (median, 11.1 months).
Here we report the clinical case of a patient with HER2 
gene amplified and RAS and BRAF WT mCRC, who expe-
rienced a long lasting and relevant clinical efficacy from 
sequential anti-HER2 therapies.
MateRIals and MetHods
Patient treatment
The patient was treated in the Division of Medical 
Oncology, Dipartimento di Internistica Clinica e Sper-
imentale ‘F Magrassi’, Università degli Studi della 
Campania L Vanvitelli, Naples, Italy. Treatments with 
anti-HER2 drugs reported here were within the HERA-
CLES cohort A clinical trial or as off-label therapies that 
were approved by the local institutional ethics committee. 
Written informed consent was obtained. Trastuzumab plus 
lapatinib were administered as reported.8 Other HER2-di-
rected treatments (trastuzumab plus pertuzumab, T-DM1, 
capecitabine plus trastuzumab) were given at standard, 
registered doses and schedules.
HeR2 gene amplification and HeR2 protein overexpression 
analyses
Primary tumour tissue was evaluated for gene amplifica-
tion and protein expression by FISH and IHC, as previ-
ously reported.12 HER2 positivity was defined according 
to HERACLES CRC-specific HER2 scoring criteria. IHC 
had to detect intense cell membrane HER2 protein 
expression in >50% of cells (3+ score). This was accom-
panied by HER2 gene amplification (HER2:CEP17 ratio 
higher than 2 in more than 50% of cells by FISH).
dna analysis for multiple assessment of gene mutations or 
amplifications
Tumour samples were analysed with either of the two 
following NGS techniques. The first biopsy (from later-
ocervical lymph node metastasis) was analysed with the 
Table 1 Ongoing clinical trials evaluating anti-HER2 treatments in mCRC
Drug Study Definition of HER2 positivity
ClinicalTrials.gov
identifier or 
EUDRACT number Phase Status
Pertuzumab 
plus T-DM1
Pertuzumab and 
trastuzumab emtansine in 
HER2-positive colorectal 
cancer
(HERACLES cohort B)
 ► 3+ HER2 score (IHC) in more than 
50% of cells
 ► 2+ HER2 score (IHC) and a 
HER2:CEP17 ratio higher than 2 in 
more than 50% of cells by FISH
2012-002128-33 II Active, 
recruiting
T-DM1 HER2 Amplification for 
Colorectal Cancer Enhanced 
Stratification—rechallenge 
with HER2 selective cytotoxic 
uptake of emtansine
(HERACLES-RESCUE)
 ► 3+ HER2 score (IHC) in more than 
50% of cells
 ► 2+ HER2 score (IHC) and a 
HER2:CEP17 ratio higher than 2 in 
more than 50% of cells by FISH
2015-003275-30 II Active, 
recruiting
Pertuzumab 
plus 
trastuzumab
A study evaluating Herceptin/
Perjeta, Tarceva, Zelboraf/
Cotellic, and Erivedge 
treatment targeted against 
certain mutations in cancer 
patients (My Pathway)
 ► HER2 overexpression, 
amplification or HER2-activating 
mutation
NCT02091141 II Active, 
recruiting
Tucatinib plus 
trastuzumab
Tucatinib (ONT-380) and 
trastuzumab for patients 
with HER2-positive 
metastatic colorectal cancer 
(MOUNTAINEER)
 ► HER2 overexpression (3+ IHC). 
HER2 2+ IHC is eligible if the 
tumour is amplified by FISH.
 ► HER2 amplification by in situ 
hybridisation assay (FISH or CISH 
signal ratio >2.0 or gene copy 
number >6)
 ► HER2 amplification by CLIA-
certified NGS sequencing assay
NCT03043313 II Not yet 
recruiting
CISH, chromogenic in situ hybridisation; CLIA, Clinical Laboratory Improvement Amendments; EUDRACT, European Clinical Trials 
Database; FISH, fluorescence in situ hybridisation; HERACLES, HER2 Amplification for Colorectal Cancer Enhanced Stratification; IHC, 
immunohistochemistry; mCRC, metastatic colorectal cancer; NGS, next-generation sequencing; T-DM1, trastuzumab emtansine. 
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Ion AmpliSeq Colon and Lung Cancer Panel (Life Tech-
nologies) using Ion Torrent semiconductor sequencing, 
as previously reported15 16 (see online supplementary 
appendix A for details). The second biopsy (from one 
of the liver metastases) was analysed by using a more 
extensive targeted high-multiplex PCR-based NGS 
panel (OncoMine Comprehensive Assay), as previously 
described17 (see online supplementary appendix A for 
details).
Results
A 42-year-old Caucasian man was diagnosed in April 2013 
with adenocarcinoma of the left colon at colonoscopy. A 
CT scan ruled out distant metastasis. Thus, in May 2013 
the patient underwent potential radical surgery (left 
hemicolectomy: pT4aG1N1bM0, IIIB stage). 5-Fluoro-
uracil, leucovorin and oxaliplatin (FOLFOX) adjuvant 
treatment was planned. However, before starting it, the 
physical evaluation of the patient detected a left latero-
cervical lymph node enlargement. A biopsy confirmed 
the diagnosis of lymph node metastasis from colon 
adenocarcinoma. DNA was extracted from this metastatic 
site. Multiple gene mutation analysis by NGS of a selected 
panel of 22 genes (see online supplementary appendix A 
for details)15 16 found no gene mutations, including KRAS, 
NRAS, BRAF, PIK3CA, but detected HER2 gene amplifi-
cation. A new CT scan revealed several additional abdom-
inal lymph node lesions. In June 2013, the patient started 
first-line treatment for metastatic disease with folinic 
acid, fluorouracil & irinotecan plus cetuximab. The 
best response was SD with PFS of 5 months. A CT scan 
demonstrated progression of disease in the left laterocer-
vical lymph nodes and the appearance of novel bilateral 
lung lesions. Therefore, the patient started second-line 
treatment with FOLFOX plus bevacizumab. This therapy 
achieved a minor response as best response with PFS of 
6 months, when further progression in lung metastases 
and abdominal lymph nodes was found. A third-line 
treatment with regorafenib was started, but the patient's 
clinical conditions rapidly deteriorated. Within 3 months, 
the performance status (PS) declined to 2 with reduction 
of normal physical activities, fatigue and abdominal pain 
requiring high doses of opioids. Thus, having no standard 
therapeutic options after regorafenib failure, despite the 
rapid worsening of the clinical conditions, we evaluated if 
the patient could receive an experimental therapy within 
a clinical trial. Since the patient had a tumour with HER2 
gene amplification as detected by NGS performed on the 
first laterocervical lymph node metastasis, the primary 
tumour was also analysed. HER2 overexpression by IHC 
with 3+ positive scoring was found. Central laboratory 
review confirmed HER2 gene amplification by FISH. The 
patient was, therefore, eligible for treatment in the phase 
II HERACLES cohort A clinical trial. On October 2014, 
treatment with trastuzumab and lapatinib (as fourth line 
of therapy for mCRC) was started. Within 1 week of treat-
ment, PS score restored to 0 with resolution of abdominal 
pain and no more opioid therapy requirement. The treat-
ment was well tolerated. The patient resumed normal life 
including work and sports activities. The first CT scan reas-
sessment demonstrated a PR (figure 1), which lasted until 
September 2015 with a total of 16 courses of trastuzumab 
and lapatinib administered and a PFS of 12 months. At 
that time, novel lung metastatic lesions were detected. 
Despite the progression of disease, the patient main-
tained PS 0. Therefore, based on the clinical evidence 
that continuing the HER2 blockade is associated with 
improved outcome in metastatic breast cancer,18 we asked 
our institutional ethics committee the authorisation for 
an off-label treatment with pertuzumab plus trastuzumab. 
The patient was treated from October 2015 to July 2016 
with this combination (as fifth line), achieving as best 
response SD and a PFS of 10 months. However, for the 
first time multiple liver metastases were detected together 
with novel lung and lymph node metastases. PS worsened 
to 2 and opioid treatment was restarted. A biopsy of a liver 
lesion was obtained and was analysed by NGS for a panel 
of 143 genes (see online supplementary appendix A for 
details).17 HER2 gene amplification (with 70% allele 
frequency) was confirmed, while a novel TP53p.R175H 
gene mutation (c.524G>A, 70.4% allele frequency) was 
found. No mutations or amplifications were found in 
KRAS, NRAS, BRAF, AKT, PIK3CA, EGFR, HER3, MET 
as well as in other genes that could be involved in HER 
family-activated pathways. Considering the persistence 
of HER2 gene amplification, without any other gene 
alterations, that could be targeted with a selective molec-
ular approach, in August 2016 the patient received, as 
off-label therapy and after ethics committee approval, the 
Figure 1 (A) Chest CT image before starting trastuzumab 
plus lapatinib. (B) Chest CT image after 8 weeks of 
trastuzumab plus lapatinib therapy.
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first course of T-DM1 therapy. Best response was SD with 
an improvement of clinical conditions to PS 0 and PFS of 
5 months. In December 2016, following lung, liver and 
abdominal lymph nodes disease progression, the clin-
ical conditions worsened rapidly to PS 3 with dyspnoea 
requiring oxygen supplementation, lower limbs oedema 
and abdominal pain. Oral capecitabine plus trastuzumab 
treatment was started. Symptoms improved to PS 1 within 
three cycles. As of 6 April 2017, the patient was still on 
treatment. A summary of the anticancer treatments is 
illustrated in table 2.
dIsCussIon
Constitutive activation of HER2-dependent intracel-
lular signalling by HER2 gene amplification or by HER2 
mutations has been demonstrated as a mechanism of 
cancer resistance to cetuximab or panitumumab in 
PDTX models of mCRC.6 Furthermore, the HERA-
CLES diagnostic and therapeutic research programme 
has demonstrated that HER2 gene amplification is 
detected in a subgroup of patients with mCRC.8 This 
correlated with intrinsic cancer resistance to anti-EGFR 
moAbs in KRAS exon 2 WT tumours. Both HERACLES 
cohort A and My Pathway clinical trials provided clin-
ical evidence that anti-HER2 therapies could be active 
in these patients.13 14
The clinical case, which is reported here, highlights 
the role of HER2 gene amplification as a key genetic 
driver of cancer development and progression. In fact, 
HER2 gene amplification was detected in the primary 
tumour as well as in two metastatic sites (laterocervical 
lymph node and liver metastases) that emerged during 
clinical progression. Sequential HER2-directed ther-
apies were a highly effective therapeutic strategy after 
failure of standard treatments for mCRC. In this respect, 
a cumulative clinical benefit of 29 months with sequen-
tial lines of HER2 blockade was achieved, whereas the 
first three lines of standard treatments, which included 
all the potentially active drugs in mCRC, accounted for 
only 14 months of disease control. Further, HER2-di-
rected therapies were very well tolerated with no grade 
3/4 toxicities and with no heart function impairment. 
These results confirm that anti-HER2 therapies are 
highly effective in patients with HER2-amplified mCRC 
and suggest that sequential HER2 blockade could be a 
potential therapeutic strategy.
Taken together, a large body of preclinical and clinical 
evidence, including this case report, supports the need 
to identify HER2 gene amplification in mCRC. In fact, 
although this genetic alteration occurs at low frequency, 
it defines a relatively homogeneous subset of patients 
with mCRC with intrinsic resistance to EGFR-targeted 
therapy and that could have a significant clinical benefit 
from anti-HER2 treatments.
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